Skip to content

Study · Ex vivo tissue · mouse and rat · 2011

3 results

Continuous on-line monitoring of secretion from rodent pituitary endocrine cells using fluorescent protein surrogate markers.

He Z, Fernandez-Fuente M, Strom M, Cheung L, Robinson IC, Le Tissier P

Journal of neuroendocrinology1 Mar 2011Cited by 13 (Europe PMC)

PMID21166728 (opens in a new tab)DOI10.1111/j.1365-2826.2010.02104.x (opens in a new tab)PepBankPUB-21166728
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In rat pituitary slices, GHRP‑6 exposure changed fluorescent protein output in correlation with hormone secretion.

    In plain wordsIn lab tests, GHRP‑6 changed fluorescent marker release in correlation with hormone release.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedFluorescent protein output
    Study

    ratn: not reported in source

    pituitary tissue slices
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Brief exposures of vibratome slices to GH secretagogues [GH-releasing hormone (GHRH), GH-releasing peptide-6 (GHRP-6)] or somatostatin caused changes in FP output that correlate with hormone secretion, subsequently measured in fractions of perfusate by radioimmunoassay.
    1 context sentence
    Summary · context
    We have tested this system using GH-GFP transgenic rats with green fluorescent protein (GFP) targeted to the secretory vesicles (SVs) of pituitary growth hormone (GH) cells.
  2. 02LabEx vivo tissueActivity measurement

    In rat pituitary slices, the method detected differences in response kinetics to GHRP‑6 between wild-type and dwarf rats.

    In plain wordsIn lab tests, response timing after GHRP‑6 differed between wild-type and dwarf rat tissue.

    Peptide
    GHRP-6
    Outcome
    Direction not reportedResponse kinetics
    Study

    ratn: not reported in source

    pituitary tissue slices
    Comparator
    wild-type versus dwarf rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The temporal resolution of this method was capable of revealing differences in the kinetics of response to GHRH and GHRP-6 between wild-type and dwarf (dw/dw) rats harbouring the GH-GFP transgene.
    1 context sentence
    Summary · context
    We have tested this system using GH-GFP transgenic rats with green fluorescent protein (GFP) targeted to the secretory vesicles (SVs) of pituitary growth hormone (GH) cells.
  3. 03LabEx vivo tissueActivity measurement

    In transgenic mouse pituitary slices, low oxytocin concentrations stimulated monomeric RFP secretion in a dose-dependent manner.

    In plain wordsIn lab tests, low oxytocin concentrations increased fluorescent marker release from mouse pituitary tissue in a dose-dependent manner.

    Peptide
    Oxytocin
    Outcome
    IncreaseMonomeric RFP secretion
    Study

    mousen: not reported in source

    transgenic lactotroph pituitary slices
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The inhibition of monomeric RFP secretion by dopamine was dose-dependent, as was stimulation by low concentrations of oxytocin.
    1 context sentence
    Summary · context
    We further tested the utility of the system by generating transgenic mice with red FPs targeted to secretory vesicles (PRL-mRFP(sv)) and to the cytoplasm (PRL-DsRed(cyto)) of lactotrophs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:13 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:52 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.